

Markus Peter Schlaich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3240546/publications.pdf>

Version: 2024-02-01

374
papers

28,348
citations

10956

71
h-index

6454

157
g-index

377
all docs

377
docs citations

377
times ranked

20272
citing authors

#	ARTICLE	IF	CITATIONS
1	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	6.3	3,928
2	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2) Tj ETQq0 0 0 rgBT /Overlock 10	6.3	2,002
3	Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. <i>Lancet, The</i> , 2009, 373, 1275-1281.	6.3	1,918
4	2020 International Society of Hypertension Global Hypertension Practice Guidelines. <i>Hypertension</i> , 2020, 75, 1334-1357.	1.3	1,895
5	Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension. <i>New England Journal of Medicine</i> , 2009, 361, 932-934.	13.9	702
6	Renin-angiotensin system and cardiovascular risk. <i>Lancet, The</i> , 2007, 369, 1208-1219.	6.3	583
7	Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. <i>Lancet, The</i> , 2014, 383, 622-629.	6.3	556
8	Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension. <i>Circulation</i> , 2011, 123, 1940-1946.	1.6	541
9	2020 International Society of Hypertension global hypertension practice guidelines. <i>Journal of Hypertension</i> , 2020, 38, 982-1004.	0.3	452
10	Sympathetic Augmentation in Hypertension. <i>Hypertension</i> , 2004, 43, 169-175.	1.3	451
11	Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. <i>Circulation</i> , 2012, 126, 2976-2982.	1.6	420
12	Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy. <i>Circulation</i> , 2003, 108, 560-565.	1.6	393
13	Sympathetic Activation in Chronic Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 933-939.	3.0	371
14	Substantial Reduction in Single Sympathetic Nerve Firing After Renal Denervation in Patients With Resistant Hypertension. <i>Hypertension</i> , 2013, 61, 457-464.	1.3	331
15	Renal Denervation in Moderate to Severe CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1250-1257.	3.0	322
16	Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension. <i>Hypertension</i> , 2012, 60, 419-424.	1.3	289
17	Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-11.	1.0	273
18	Sympathetic nervous activation in obesity and the metabolic syndromeâ€™Causes, consequences and therapeutic implications. , 2010, 126, 159-172.		267

#	ARTICLE	IF	CITATIONS
19	Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk?. Journal of Hypertension, 2007, 25, 2117-2124.	0.3	259
20	May Measurement Month 2017: an analysis of blood pressure screening results worldwide. The Lancet Global Health, 2018, 6, e736-e743.	2.9	245
21	Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension. Circulation, 2013, 128, 132-140.	1.6	240
22	Guideline for the diagnosis and management of hypertension in adults " 2016. Medical Journal of Australia, 2016, 205, 85-89.	0.8	236
23	Increased Bioavailability of Nitric Oxide After Lipid-Lowering Therapy in Hypercholesterolemic Patients. Circulation, 1998, 98, 211-216.	1.6	234
24	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal, 2014, 35, 1752-1759.	1.0	227
25	Interactions Between Leptin and the Human Sympathetic Nervous System. Hypertension, 2003, 41, 1072-1079.	1.3	223
26	Renal Denervation as a Therapeutic Approach for Hypertension. Hypertension, 2009, 54, 1195-1201.	1.3	220
27	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal, 2019, 40, 2006-2017.	1.0	193
28	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. European Heart Journal, 2019, 40, 3474-3482.	1.0	189
29	Differing Pattern of Sympathoexcitation in Normal-Weight and Obesity-Related Hypertension. Hypertension, 2007, 50, 862-868.	1.3	181
30	Sympathetic Nervous System Activity Is Associated With Obesity-Induced Subclinical Organ Damage in Young Adults. Hypertension, 2010, 56, 351-358.	1.3	174
31	First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension. Hypertension, 2015, 65, 766-774.	1.3	172
32	May Measurement Month 2019. Hypertension, 2020, 76, 333-341.	1.3	157
33	Sympatho-renal axis in chronic disease. Clinical Research in Cardiology, 2011, 100, 1049-1057.	1.5	155
34	SGLT2 Inhibitor-Induced Sympathoinhibition. JACC Basic To Translational Science, 2020, 5, 169-179.	1.9	152
35	Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. Journal of Hypertension, 2017, 35, 2059-2068.	0.3	150
36	Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. European Heart Journal, 2014, 35, 2224-2231.	1.0	140

#	ARTICLE	IF	CITATIONS
37	Reinnervation of Renal Afferent and Efferent Nerves at 5.5 and 11 Months After Catheter-Based Radiofrequency Renal Denervation In Sheep. <i>Hypertension</i> , 2015, 65, 393-400.	1.3	140
38	Increased Wall:Lumen Ratio of Retinal Arterioles in Male Patients With a History of a Cerebrovascular Event. <i>Hypertension</i> , 2007, 50, 623-629.	1.3	139
39	New drugs, procedures, and devices for hypertension. <i>Lancet, The</i> , 2012, 380, 591-600.	6.3	139
40	Device-Based Antihypertensive Therapy. <i>Circulation</i> , 2011, 123, 209-215.	1.6	136
41	CHRONIC MENTAL STRESS IS A CAUSE OF ESSENTIAL HYPERTENSION: PRESENCE OF BIOLOGICAL MARKERS OF STRESS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 498-502.	0.9	134
42	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2012, 30, 1047-1055.	0.3	134
43	Sustained Sympathetic and Blood Pressure Reduction 1 Year After Renal Denervation in Patients With Resistant Hypertension. <i>Hypertension</i> , 2014, 64, 118-124.	1.3	132
44	Renal denervation: a potential new treatment modality for polycystic ovary syndrome?. <i>Journal of Hypertension</i> , 2011, 29, 991-996.	0.3	124
45	International Expert Consensus Statement. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2031-2045.	1.2	124
46	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2013, 168, 2214-2220.	0.8	122
47	Impaired L-Arginine Transport and Endothelial Function in Hypertensive and Genetically Predisposed Normotensive Subjects. <i>Circulation</i> , 2004, 110, 3680-3686.	1.6	120
48	Metabolic syndrome: a sympathetic disease?. <i>Lancet Diabetes and Endocrinology, the</i> , 2015, 3, 148-157.	5.5	118
49	Point: Chronic Activation of the Sympathetic Nervous System is the Dominant Contributor to Systemic Hypertension. <i>Journal of Applied Physiology</i> , 2010, 109, 1996-1998.	1.2	113
50	Ambulatory blood pressure monitoring in Australia. <i>Journal of Hypertension</i> , 2012, 30, 253-266.	0.3	109
51	Gender differences in sympathetic nervous activity: influence of body mass and blood pressure. <i>Journal of Hypertension</i> , 2007, 25, 1411-1419.	0.3	108
52	Sympathetic Neural Adaptation to Hypocaloric Diet With or Without Exercise Training in Obese Metabolic Syndrome Subjects. <i>Diabetes</i> , 2010, 59, 71-79.	0.3	104
53	Role of the Sympathetic Nervous System and Its Modulation in Renal Hypertension. <i>Frontiers in Medicine</i> , 2018, 5, 82.	1.2	104
54	Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1351-1358.	1.2	103

#	ARTICLE	IF	CITATIONS
55	Neuroadrenergic Dysfunction Along the Diabetes Continuum. <i>Diabetes</i> , 2012, 61, 2506-2516.	0.3	101
56	Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 1426-1433.	2.2	101
57	The Effects of Weight Loss <i>versus</i> Weight Loss Maintenance on Sympathetic Nervous System Activity and Metabolic Syndrome Components. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E503-E508.	1.8	97
58	Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. <i>Journal of Hypertension</i> , 2010, 28, 543-550.	0.3	95
59	Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. <i>Journal of Hypertension</i> , 2011, 29, 553-564.	0.3	93
60	Analysis of retinal arteriolar structure in never-treated patients with essential hypertension. <i>Journal of Hypertension</i> , 2008, 26, 1427-1434.	0.3	90
61	Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 27-36.	2.2	90
62	The role of sympathetic nervous activity in renal injury and end-stage renal disease. <i>Hypertension Research</i> , 2010, 33, 521-528.	1.5	90
63	European Society of Hypertension position paper on renal denervation 2021. <i>Journal of Hypertension</i> , 2021, 39, 1733-1741.	0.3	88
64	Human Sympathetic Nerve Biology. <i>Annals of the New York Academy of Sciences</i> , 2008, 1148, 338-348.	1.8	84
65	The Role of Renal Denervation in the Treatment of Heart Failure. <i>Current Cardiology Reports</i> , 2012, 14, 285-292.	1.3	83
66	Role of the Sympathetic Nervous System in Stress-Mediated Cardiovascular Disease. <i>Current Hypertension Reports</i> , 2015, 17, 80.	1.5	82
67	Relation between QT interval variability and cardiac sympathetic activity in hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H1412-H1417.	1.5	80
68	Renal Denervation in High-Risk Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2879-2888.	1.2	80
69	Altered Sympathetic Nervous Reactivity and Norepinephrine Transporter Expression in Patients With Postural Tachycardia Syndrome. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2008, 1, 103-109.	2.1	79
70	Assessment of endothelial function of the renal vasculature in human subjects. <i>American Journal of Hypertension</i> , 2002, 15, 3-9.	1.0	75
71	Renal Denervation Update From the International Sympathetic Nervous System Summit. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3006-3017.	1.2	74
72	Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. <i>Lancet</i> , 2021, 398, 1043-1052.	6.3	74

#	ARTICLE	IF	CITATIONS
73	The neuronal noradrenaline transporter, anxiety and cardiovascular disease. <i>Journal of Psychopharmacology</i> , 2006, 20, 60-66.	2.0	73
74	Health-Related Quality of Life After Renal Denervation in Patients With Treatment-Resistant Hypertension. <i>Hypertension</i> , 2012, 60, 1479-1484.	1.3	72
75	Chrelin Modulates Sympathetic Nervous System Activity and Stress Response in Lean and Overweight Men. <i>Hypertension</i> , 2011, 58, 43-50.	1.3	70
76	New developments in the pathogenesis of obesity-induced hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1499-1508.	0.3	68
77	Effects of Renal Denervation on Sympathetic Activation, Blood Pressure, and Glucose Metabolism in Patients with Resistant Hypertension. <i>Frontiers in Physiology</i> , 2012, 3, 10.	1.3	67
78	Renal nerve ablation reduces augmentation index in patients with resistant hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1893-1900.	0.3	66
79	Surgical approaches to the treatment of obesity. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 429-437.	8.2	64
80	Renal Denervation and Hypertension. <i>American Journal of Hypertension</i> , 2011, 24, 635-642.	1.0	63
81	Rapid Nongenomic Effects of Aldosterone on the Renal Vasculature in Humans. <i>Hypertension</i> , 2006, 47, 650-655.	1.3	62
82	Renal Denervation Reduces Monocyte Activation and Monocyte-Platelet Aggregate Formation. <i>Hypertension</i> , 2017, 69, 323-331.	1.3	61
83	Renal Denervation for Treating Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1095-1105.	1.1	61
84	Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance. <i>Clinical Endocrinology</i> , 2015, 83, 812-819.	1.2	60
85	Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach Focus on treatment by antihypertensive agents. <i>American Journal of Hypertension</i> , 1998, 11, 1394-1404.	1.0	59
86	Dyslipidemia Is Associated With Sympathetic Nervous Activation and Impaired Endothelial Function in Young Females. <i>American Journal of Hypertension</i> , 2013, 26, 250-256.	1.0	59
87	Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E744-E752.	1.8	58
88	Reverse cardiac remodeling after renal denervation: Atrial electrophysiologic and structural changes associated with blood pressure lowering. <i>Heart Rhythm</i> , 2015, 12, 982-990.	0.3	58
89	Sympathetic and cardiac baroreflex function in panic disorder. <i>Journal of Hypertension</i> , 2002, 20, 2445-2451.	0.3	57
90	Sustained Decrease in Blood Pressure and Reduced Anatomical and Functional Reinnervation of Renal Nerves in Hypertensive Sheep 30 Months After Catheter-Based Renal Denervation. <i>Hypertension</i> , 2019, 73, 718-727.	1.3	57

#	ARTICLE	IF	CITATIONS
91	Does Lipoprotein(a) Impair Endothelial Function?. Journal of the American College of Cardiology, 1998, 31, 359-365.	1.2	56
92	Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. American Journal of Cardiology, 2000, 85, 1199-1206.	0.7	56
93	Effect of renal denervation on kidney function in patients with chronic kidney disease. International Journal of Cardiology, 2017, 232, 93-97.	0.8	56
94	Rationale and design of a large registry on renal denervation: the Global SYMPPLICITY registry. EuroIntervention, 2013, 9, 484-492.	1.4	56
95	1166 A/C Polymorphism of the Angiotensin II Type 1 Receptor Gene and the Response to Short-Term Infusion of Angiotensin II. Circulation, 1999, 100, 1394-1399.	1.6	55
96	Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement. Medical Journal of Australia, 2020, 213, 182-187.	0.8	54
97	Single-unit muscle sympathetic nervous activity and its relation to cardiac noradrenaline spillover. Journal of Physiology, 2011, 589, 2597-2605.	1.3	53
98	Weight Loss May Reverse Blunted Sympathetic Neural Responsiveness to Glucose Ingestion in Obese Subjects With Metabolic Syndrome. Diabetes, 2009, 58, 1126-1132.	0.3	51
99	The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. British Journal of Pharmacology, 2019, 176, 1839-1852.	2.7	51
100	Obesity Paradox in Hypertension. Hypertension, 2018, 71, 22-33.	1.3	50
101	Novel procedure- and device-based strategies in the management of systemic hypertension. European Heart Journal, 2011, 32, 537-544.	1.0	47
102	Morning Surge in Blood Pressure Is Associated With Reactivity of the Sympathetic Nervous System. American Journal of Hypertension, 2014, 27, 783-792.	1.0	47
103	Recurrent Postural Vasovagal Syncope. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 711-718.	2.1	46
104	Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. International Journal of Hypertension, 2013, 2013, 1-9.	0.5	46
105	Sympathetic Response and Outcomes Following Renal Denervation in Patients With Chronic Heart Failure: 12-Month Outcomes From the Symplicity HF Feasibility Study. Journal of Cardiac Failure, 2017, 23, 702-707.	0.7	44
106	Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. Supportive Care in Cancer, 1999, 7, 354-361.	1.0	43
107	Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects. Current Hypertension Reports, 2012, 14, 247-253.	1.5	43
108	Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. Journal of Hypertension, 2009, 27, 2201-2208.	0.3	42

#	ARTICLE	IF	CITATIONS
109	Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2015, 104, 672-678.	1.5	42
110	PROSPECTIVE ANALYSIS OF THE VALUE OF 24-HOUR AMBULATORY BLOOD PRESSURE ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 2000, 70, 819-827.	0.5	41
111	Renal Sympathetic Nerve Ablation: The New Frontier in the Treatment of Hypertension. <i>Current Hypertension Reports</i> , 2010, 12, 39-46.	1.5	41
112	Sympathetic nervous response to ischemia-reperfusion injury in humans is altered with remote ischemic preconditioning. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H364-H370.	1.5	41
113	Facilitated defensive coping, silent ischaemia and ECG left-ventricular hypertrophy. <i>Journal of Hypertension</i> , 2012, 30, 543-550.	0.3	40
114	Catheter-Based Renal Denervation Exacerbates Blood Pressure Fall DuringÂHemorrhage. <i>Journal of the American College of Cardiology</i> , 2017, 69, 951-964.	1.2	40
115	Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation. <i>Frontiers in Neuroscience</i> , 2018, 12, 1058.	1.4	40
116	SINGLEâ€¦UNIT SYMPATHETIC DISCHARGE PATTERN IN PATHOLOGICAL CONDITIONS ASSOCIATED WITH ELEVATED CARDIOVASCULAR RISK. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 503-507.	0.9	39
117	European Society of Hypertension Working Group on Obesity Antihypertensive effects of weight loss: myth or reality?. <i>Journal of Hypertension</i> , 2010, 28, 637-643.	0.3	39
118	A polymorphism in the norepinephrine transporter gene is associated with affective and cardiovascular disease through a microRNA mechanism. <i>Molecular Psychiatry</i> , 2017, 22, 134-141.	4.1	38
119	Renal Vascular Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus. <i>American Journal of Kidney Diseases</i> , 2009, 53, 281-289.	2.1	37
120	European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. <i>Journal of Hypertension</i> , 2009, 27, 207-211.	0.3	37
121	Baseline Sympathetic Nervous System Activity Predicts Dietary Weight Loss in Obese Metabolic Syndrome Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 605-613.	1.8	36
122	Seismic architecture of a Miocene isolated carbonate platform and associated off-platform strata (Central Luconia Province, offshore Malaysia). <i>Marine and Petroleum Geology</i> , 2019, 102, 477-495.	1.5	36
123	Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2000, 153, 383-389.	0.4	34
124	Sympathetic Activity and Markers of Cardiovascular Risk in Nondiabetic Severely Obese Patients: The Effect of the Initial 10% Weight Loss. <i>American Journal of Hypertension</i> , 2014, 27, 1308-1315.	1.0	34
125	Effects of oral contraceptives on vascular endothelium in premenopausal women. <i>American Journal of Obstetrics and Gynecology</i> , 2000, 183, 28-33.	0.7	33
126	Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. <i>BMJ, The</i> , 2012, 345, e7156-e7156.	3.0	33

#	ARTICLE	IF	CITATIONS
127	Device Therapy of Hypertension. <i>Circulation Research</i> , 2021, 128, 1080-1099.	2.0	33
128	Association of (pro)renin receptor gene polymorphism with blood pressure in Caucasian men. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 347-349.	0.7	32
129	Reinnervation following catheter-based radiofrequency renal denervation. <i>Experimental Physiology</i> , 2015, 100, 485-490.	0.9	32
130	Autonomic Regulation of Glucose Homeostasis: a Specific Role for Sympathetic Nervous System Activation. <i>Current Diabetes Reports</i> , 2018, 18, 107.	1.7	30
131	Obesity-Associated Organ Damage and Sympathetic Nervous Activity. <i>Hypertension</i> , 2019, 73, 1150-1159.	1.3	30
132	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. <i>Clinical Science</i> , 2000, 99, 293-302.	1.8	29
133	Targeting the Sympathetic Nervous System. <i>Hypertension</i> , 2014, 63, 426-432.	1.3	29
134	Android Fat Deposition and Its Association With Cardiovascular Risk Factors in Overweight Young Males. <i>Frontiers in Physiology</i> , 2019, 10, 1162.	1.3	29
135	Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. <i>Journal of Hypertension</i> , 2002, 20, 117-124.	0.3	28
136	Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 2008, 196, 704-711.	0.4	28
137	Change in sympathetic nerve firing pattern associated with dietary weight loss in the metabolic syndrome. <i>Frontiers in Physiology</i> , 2011, 2, 52.	1.3	28
138	Sympathetic Activation in Chronic Kidney Disease. <i>Hypertension</i> , 2011, 57, 683-685.	1.3	28
139	Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. <i>Amino Acids</i> , 2014, 46, 321-326.	1.2	28
140	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
141	Impaired Sodium Excretion During Mental Stress in Mild Essential Hypertension. <i>Hypertension</i> , 2001, 37, 923-927.	1.3	27
142	Effects of sympathetic modulation in metabolic disease. <i>Annals of the New York Academy of Sciences</i> , 2019, 1454, 80-89.	1.8	27
143	The Role of Central Nervous System Mechanisms in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2015, 17, 58.	1.5	26
144	Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation*. <i>Journal of Hypertension</i> , 2018, 36, 1414-1422.	0.3	26

#	ARTICLE	IF	CITATIONS
145	Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. <i>Hypertension</i> , 2021, 77, 1825-1844.	1.3	26
146	From SYMPPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go?. <i>EuroIntervention</i> , 2014, 10, 21-23.	1.4	26
147	Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation. <i>EuroIntervention</i> , 2013, 9, R127-R135.	1.4	26
148	Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects. <i>American Heart Journal</i> , 1999, 138, 810-817.	1.2	25
149	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. <i>American Journal of Hypertension</i> , 1999, 12, 418-422.	1.0	24
150	Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. <i>Journal of Hypertension</i> , 2008, 26, 110-116.	0.3	24
151	Reduction in Basal Nitric Oxide Activity Causes Albuminuria. <i>Diabetes</i> , 2011, 60, 572-576.	0.3	24
152	Renal denervation: current implications and future perspectives. <i>Clinical Science</i> , 2014, 126, 41-53.	1.8	24
153	New Approaches in the Management of Sudden Cardiac Death in Patients with Heart Failure—Targeting the Sympathetic Nervous System. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2430.	1.8	24
154	Current Knowledge of IL-6 Cytokine Family Members in Acute and Chronic Kidney Disease. <i>Biomedicines</i> , 2019, 7, 19.	1.4	24
155	Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. <i>Clinical Science</i> , 2000, 98, 521-529.	1.8	23
156	Angiotensin II and norepinephrine release: interaction and effects on the heart. <i>Journal of Hypertension</i> , 2005, 23, 1077-1082.	0.3	23
157	Does renalase degrade catecholamines?. <i>Kidney International</i> , 2011, 79, 1380.	2.6	23
158	Percutaneous transluminal renal denervation: A potential treatment option for polycystic kidney disease-related pain?. <i>International Journal of Cardiology</i> , 2013, 162, e58-e59.	0.8	23
159	Opposing effects of shear-mediated dilation and myogenic constriction on artery diameter in response to handgrip exercise in humans. <i>Journal of Applied Physiology</i> , 2015, 119, 858-864.	1.2	23
160	Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension. <i>Journal of Hypertension</i> , 2017, 35, 148-153.	0.3	23
161	The Relation of Glucose Metabolism to Left Ventricular Mass and Function and Sympathetic Nervous System Activity in Obese Subjects With Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E227-E237.	1.8	22
162	A Randomized Controlled Trial of the Effects of Pioglitazone Treatment on Sympathetic Nervous System Activity and Cardiovascular Function in Obese Subjects With Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1701-E1707.	1.8	22

#	ARTICLE	IF	CITATIONS
163	Chronic depression symptoms and salivary NOx are associated with retinal vascular dysregulation: The SABPA study. Nitric Oxide - Biology and Chemistry, 2016, 55-56, 10-17.	1.2	22
164	Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPPLICITY Registry with follow-up data of 3 years. Nephrology Dialysis Transplantation, 2022, 37, 304-310.	0.4	22
165	2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. Journal of Human Hypertension, 2023, 37, 428-437.	1.0	22
166	Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. Journal of Hypertension, 1999, 17, 1933-1939.	0.3	21
167	Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clinical Research in Cardiology, 2016, 105, 755-762.	1.5	21
168	Is it time to think about the sodium glucose co-transporter 2 sympathetically?. Nephrology, 2016, 21, 286-294.	0.7	21
169	The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 344-352.	1.0	21
170	Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies. Obesity, 2017, 25, 1894-1902.	1.5	21
171	Catheter-based renal denervation: the next chapter begins. European Heart Journal, 2018, 39, 4144-4149.	1.0	21
172	Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) – A Condition Associated with Heightened Sympathetic Activation. International Journal of Molecular Sciences, 2021, 22, 4241.	1.8	21
173	Short-term effects of catheter-based renal denervation on cardiac sympathetic drive and cardiac baroreflex function in heart failure. International Journal of Cardiology, 2015, 190, 220-226.	0.8	20
174	Renal Nitric Oxide Deficiency and Chronic Kidney Disease in Young Sheep Born with a Solitary Functioning Kidney. Scientific Reports, 2016, 6, 26777.	1.6	20
175	Renal artery anatomy affects the blood pressure response to renal denervation in patients with resistant hypertension. International Journal of Cardiology, 2016, 202, 388-393.	0.8	20
176	Are the American Heart Association/American College of Cardiology High Blood Pressure Guidelines Fit for Global Purpose?: Thoughts From the International Society of Hypertension. Hypertension, 2018, 72, 260-262.	1.3	20
177	Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy. Bioscience Reports, 2022, 42, .	1.1	20
178	The effects of dietary weight loss on indices of norepinephrine turnover: Modulatory influence of hyperinsulinemia. Obesity, 2014, 22, 652-662.	1.5	19
179	Association of vitamin D status and blood pressure response after renal denervation. Clinical Research in Cardiology, 2014, 103, 41-47.	1.5	19
180	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension. Journal of Hypertension, 2016, 34, 2480-2486.	0.3	19

#	ARTICLE	IF	CITATIONS
181	The role of renal sympathetic nerves in ischemia reperfusion injury. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017, 204, 105-111.	1.4	19
182	A polymorphism in the noradrenaline transporter gene is associated with increased blood pressure in patients with resistant hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1571-1577.	0.3	19
183	Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-8.	0.6	19
184	Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension. <i>EuroIntervention</i> , 2018, 14, 121-128.	1.4	19
185	Endothelial Function in Healthy Young Individuals Is Associated with Dietary Consumption of Saturated Fat. <i>Frontiers in Physiology</i> , 2017, 8, 876.	1.3	18
186	Comparison of Commonly Used Questionnaires to Identify Obstructive Sleep Apnea in a High-Risk Population. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 2057-2064.	1.4	18
187	Sympathetic Activation in Hypertensive Chronic Kidney Disease – A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?. <i>Frontiers in Physiology</i> , 2019, 10, 1546.	1.3	18
188	Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial. <i>Clinical Research in Cardiology</i> , 2018, 107, 642-652.	1.5	17
189	Sympathetic activity in obesity: a brief review of methods and supportive data. <i>Annals of the New York Academy of Sciences</i> , 2019, 1454, 56-67.	1.8	17
190	Facies, depositional environments, and anatomy of the Subis build-up in Sarawak, Malaysia: implications on other Miocene isolated carbonate build-ups. <i>Facies</i> , 2019, 65, 1.	0.7	17
191	Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. <i>World Journal of Gastroenterology</i> , 2020, 26, 3225-3235.	1.4	17
192	Effects of Acute and Chronic Stress on the L-Arginine Nitric Oxide Pathway in Black and White South Africans. <i>Psychosomatic Medicine</i> , 2013, 75, 751-758.	1.3	16
193	Arterial Norepinephrine Concentration is Inversely and Independently Associated With Insulin Clearance in Obese Individuals With Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1544-1550.	1.8	16
194	Renal Sympathetic Denervation: A Viable Option for Treating Resistant Hypertension. <i>American Journal of Hypertension</i> , 2017, 30, 847-856.	1.0	16
195	The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension. <i>Current Hypertension Reports</i> , 2017, 19, 99.	1.5	16
196	Shining LIGHT on the metabolic role of the cytokine TNFSF14 and the implications on hepatic IL-6 production. <i>Immunology and Cell Biology</i> , 2018, 96, 41-53.	1.0	16
197	Adrenoceptor-mediated, nitric-oxide-dependent vasodilatation is abnormal in early hypertension. <i>Journal of Hypertension</i> , 2004, 22, 1917-1925.	0.3	14
198	Recent advances in the treatment of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 729-744.	0.6	14

#	ARTICLE	IF	CITATIONS
199	Renal Sympathetic Nerve Ablation for Treatment-Resistant Hypertension. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, n/a-n/a.	1.1	14
200	Regulation of the sympathetic nervous system by the kidney. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 61-68.	1.0	14
201	Three-year changes of prothrombotic factors in a cohort of South Africans with a high clinical suspicion of obstructive sleep apnea. <i>Thrombosis and Haemostasis</i> , 2016, 115, 63-72.	1.8	14
202	Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer. <i>BMC Cancer</i> , 2016, 16, 151.	1.1	14
203	Ultra-low-dose quadruple combination blood pressureâ€“lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. <i>American Heart Journal</i> , 2021, 231, 56-67.	1.2	14
204	Stress Reactivity and Its Association With Increased Cardiovascular Risk: A Role for the Sympathetic Nervous System?. <i>Hypertension</i> , 2010, 55, e20; author reply e21.	1.3	13
205	Folic Acid Treatment Normalizes NOSâ€™Dependence of Vascular Tone in the Metabolic Syndrome. <i>Obesity</i> , 2011, 19, 960-967.	1.5	13
206	Reduction in peripheral vascular resistance predicts improvement in insulin clearance following weight loss. <i>Cardiovascular Diabetology</i> , 2015, 14, 113.	2.7	13
207	Anatomical and procedural determinants of catheter-based renal denervation. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 474-479.	0.3	13
208	May Measurement Month 2017: Results of 39 national blood pressure screening programmes. <i>European Heart Journal Supplements</i> , 2019, 21, D1-D4.	0.0	13
209	Successful renal denervation decreases the platelet activation status in hypertensive patients. <i>Cardiovascular Research</i> , 2020, 116, 202-210.	1.8	13
210	May Measurement Month 2019: results of blood pressure screening from 47 countries. <i>European Heart Journal Supplements</i> , 2021, 23, B1-B5.	0.0	13
211	Retinal capillary rarefaction is associated with arterial and kidney damage in hypertension. <i>Scientific Reports</i> , 2021, 11, 1001.	1.6	13
212	Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. <i>Clinical Science</i> , 2000, 98, 521.	1.8	12
213	New Therapeutic Approaches to Resistant Hypertension. <i>Current Hypertension Reports</i> , 2010, 12, 296-302.	1.5	12
214	Device-based approaches for renal nerve ablation for hypertension and beyond. <i>Frontiers in Physiology</i> , 2015, 6, 193.	1.3	12
215	The effect of renal denervation on endothelial function and inflammatory markers in patients with resistant hypertension. <i>International Journal of Cardiology</i> , 2015, 188, 96-98.	0.8	12
216	Renal Denervationâ€™Ready for Prime Time!?. <i>Hypertension</i> , 2018, 72, 287-290.	1.3	12

#	ARTICLE	IF	CITATIONS
217	Female Gender Is Associated with Higher Susceptibility of Weight Induced Arterial Stiffening and Rise in Blood Pressure. <i>Journal of Clinical Medicine</i> , 2021, 10, 3479.	1.0	12
218	SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Being. <i>Biomedicines</i> , 2020, 8, 514.	1.4	11
219	Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension. <i>BMJ Open</i> , 2021, 11, e043625.	0.8	11
220	Effects of testosterone treatment, with and without exercise training, on ambulatory blood pressure in middle-aged and older men. <i>Clinical Endocrinology</i> , 2021, 95, 176-186.	1.2	11
221	Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition. <i>Current Hypertension Reports</i> , 2022, 24, 67-74.	1.5	11
222	Uncontrolled blood pressure in Australia: a call to action. <i>Medical Journal of Australia</i> , 2022, 216, 61-63.	0.8	11
223	Hypercholesterolaemia and treatment with statins do not alter L-arginine-induced changes of renal haemodynamics. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1758-1765.	0.4	10
224	Effects of renal denervation on insulin resistance. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1381-1386.	0.6	10
225	Blood Pressure and Sympathetic Nervous System Response to Renal Denervation. <i>Hypertension</i> , 2013, 61, e13.	1.3	10
226	Overexpression and knock-down studies highlight that a disintegrin and metalloproteinase 28 controls proliferation and migration in human prostate cancer. <i>Medicine (United States)</i> , 2016, 95, e5085.	0.4	10
227	Serum uric acid and the relationship with subclinical organ damage in adults. <i>Journal of Hypertension</i> , 2017, 35, 745-752.	0.3	10
228	The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice. <i>International Journal of Molecular Sciences</i> , 2017, 18, 884.	1.8	10
229	Inverse association between sympathetic nervous system activity and bone mass in middle aged overweight individuals. <i>Bone</i> , 2018, 111, 123-128.	1.4	10
230	Effect of Pupil Dilation with Tropicamide on Retinal Vascular Caliber. <i>Ophthalmic Epidemiology</i> , 2019, 26, 400-407.	0.8	10
231	Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model. <i>Clinical Research in Cardiology</i> , 2021, 110, 740-753.	1.5	10
232	Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes. <i>Bioscience Reports</i> , 2021, 41, .	1.1	10
233	Nocturnal hypertension: a common phenotype in a tertiary clinical setting associated with increased arterial stiffness and central blood pressure. <i>Journal of Hypertension</i> , 2021, 39, 250-258.	0.3	10
234	Lipoprotein (a) and Hypertension. <i>Current Hypertension Reports</i> , 2021, 23, 44.	1.5	10

#	ARTICLE	IF	CITATIONS
235	Hypertension in stroke survivors and associations with national premature stroke mortality: data for 2.5 million participants from multinational screening campaigns. <i>The Lancet Global Health</i> , 2022, 10, e1141-e1149.	2.9	10
236	Is L-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. <i>Clinical Science</i> , 2000, 99, 293.	1.8	9
237	Advances in Sympathetic Nerve Recording in Humans. <i>Frontiers in Physiology</i> , 2012, 3, 11.	1.3	9
238	What we need to know about renal nerve ablation for treatment of hypertension and other states of sympathetic overactivity. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F1267-F1270.	1.3	9
239	The Effect of Renal Denervation on Plasma Adipokine Profile in Patients with Treatment Resistant Hypertension. <i>Frontiers in Physiology</i> , 2017, 8, 369.	1.3	9
240	ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice. <i>Mediators of Inflammation</i> , 2017, 2017, 1-9.	1.4	9
241	Pharmacotherapeutic strategies for treating hypertension in patients with obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 643-651.	0.9	9
242	Capillary vascular density in the retina of hypertensive patients is associated with a non-dipping pattern independent of mean ambulatory blood pressure. <i>Journal of Hypertension</i> , 2021, 39, 1826-1834.	0.3	9
243	Bexagliflozin for type 2 diabetes: an overview of the data. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2095-2103.	0.9	9
244	Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?. <i>Journal of Hypertension</i> , 2010, 28, 1809-1810.	0.3	8
245	Impact of nurse-mediated management on achieving blood pressure goal levels in primary care: Insights from the Valsartan Intensified Primary care Reduction of Blood Pressure Study. <i>European Journal of Cardiovascular Nursing</i> , 2016, 15, 409-416.	0.4	8
246	Muscle Sympathetic Nerve Activity Is Associated With Elements of the Plasma Lipidomic Profile in Young Asian Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2059-2068.	1.8	8
247	Multivariable Analysis of Patients With Severe Persistent Postprocedural Hypotension After Carotid Artery Stenting. <i>Journal of Endovascular Therapy</i> , 2019, 26, 759-767.	0.8	8
248	Contribution of the Renal Nerves to Hypertension in a Rabbit Model of Chronic Kidney Disease. <i>Hypertension</i> , 2020, 76, 1470-1479.	1.3	8
249	MicroRNA-132 may be associated with blood pressure and liver steatosis—preliminary observations in obese individuals. <i>Journal of Human Hypertension</i> , 2022, 36, 911-916.	1.0	8
250	The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy. <i>Biomedicines</i> , 2022, 10, 522.	1.4	8
251	Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocintentan. <i>Journal of Clinical Hypertension</i> , 2022, 24, 804-813.	1.0	8
252	Involvement of endothelial mechanisms in L-arginine-induced alterations of renal haemodynamics in humans. <i>Journal of Hypertension</i> , 2007, 25, 1515-1516.	0.3	7

#	ARTICLE	IF	CITATIONS
253	Left-Ventricular Structure and Function Are Influenced by Angiotensinogen Gene Polymorphism (âˆ²20) Tj ETQq1 1 0,784314,rgBT /Over	1.0	7
254	Renal nerve ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies. International Journal of Cardiology, 2012, 159, e35-e36.	0.8	7
255	Health-related quality of life and blood pressure 12 months after renal denervation. Journal of Hypertension, 2015, 33, 2350-2358.	0.3	7
256	Central arteriovenous anastomosis in resistant hypertension?. Lancet, The, 2015, 385, 1596-1597.	6.3	7
257	Device Therapies for Resistant Hypertension. Clinical Therapeutics, 2016, 38, 2152-2158.	1.1	7
258	Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. Journal of Hypertension, 2020, 38, 377-386.	0.3	7
259	Plasma lipocalin-2/NGAL is stable over 12Âweeks and is not modulated by exercise or dieting. Scientific Reports, 2021, 11, 4056.	1.6	7
260	Increase in Bioavailability of Nitric Oxide After Renal Denervation Improves Kidney Function in Sheep With Hypertensive Kidney Disease. Hypertension, 2021, 77, 1299-1310.	1.3	7
261	Increased pulse wave velocity in patients with an orthostatic blood pressure rise independent of other cardiovascular risk factors. Journal of Hypertension, 2021, 39, 1352-1360.	0.3	7
262	Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome. Metabolism: Clinical and Experimental, 2015, 64, 797-803.	1.5	6
263	Neck Circumference Is Associated with Muscle Sympathetic Nerve Activity in Overweight and Obese Men but Not Women. Frontiers in Physiology, 2017, 8, 203.	1.3	6
264	Blunted diuretic and natriuretic responses to acute sodium loading early after catheter-based renal denervation in normotensive sheep. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 317, R319-R327.	0.9	6
265	May Measurement Month 2017: an analysis of blood pressure screening results from Australiaâ€”South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D14-D16.	0.0	6
266	Blood pressure screening during the May Measurement Month 2017 programme in Vietnamâ€”South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D127-D129.	0.0	6
267	Relevance of Targeting the Distal Renal Artery and Branches with Radiofrequency Renal Denervation Approachesâ€”A Secondary Analysis from a Hypertensive CKD Patient Cohort. Journal of Clinical Medicine, 2019, 8, 581.	1.0	6
268	Modification of diet, exercise and lifestyle (MODEL) study: a randomised controlled trial protocol. BMJ Open, 2020, 10, e036366.	0.8	6
269	Diabetic kidney disease in type 2 diabetes: a review of pathogenic mechanisms, patient-related factors and therapeutic options. PeerJ, 2021, 9, e11070.	0.9	6
270	Features of antihypertensive therapy and real-world prescription of selective imidazoline receptor agonists in Russia vs other countries: STRAIGHT study data analysis. Terapevticheskii Arkhiv, 2021, 93, 440-448.	0.2	6

#	ARTICLE	IF	CITATIONS
271	Relationship Between the Aldosterone-to-Renin Ratio and Blood Pressure in Young Adults: A Longitudinal Study. <i>Hypertension</i> , 2021, 78, 387-396.	1.3	6
272	The Schlager mouse as a model of altered retinal phenotype. <i>Neural Regeneration Research</i> , 2020, 15, 512.	1.6	6
273	Effects of nitric oxide synthase inhibition and l-arginine on renal haemodynamics in young patients at high cardiovascular risk. <i>Atherosclerosis</i> , 2007, 192, 155-160.	0.4	5
274	Restoration of blood pressure control with pacemaker implantation in a patient with bradycardia and resistant hypertension: A case report. <i>International Journal of Cardiology</i> , 2013, 167, e38-e40.	0.8	5
275	Renal sympathetic nerve ablation for the management of resistant hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 607-614.	1.0	5
276	CrossTalk opposing view: Which technique for controlling resistant hypertension? Renal nerve ablation. <i>Journal of Physiology</i> , 2014, 592, 3937-3940.	1.3	5
277	Biomarkers for the Prediction of Blood Pressure Response to Renal Denervation. <i>Hypertension</i> , 2014, 63, 907-908.	1.3	5
278	Central Sympathetic Inhibition: a Neglected Approach for Treatment of Cardiac Arrhythmias?. <i>Current Hypertension Reports</i> , 2016, 18, 13.	1.5	5
279	Renal Denervation After the SPYRAL HTN-OFF MED Trial. <i>Hypertension</i> , 2017, 70, 1076-1079.	1.3	5
280	Soluble vascular endothelial growth factor receptor-1 is reduced in patients with resistant hypertension after renal denervation. <i>Journal of Human Hypertension</i> , 2017, 31, 248-252.	1.0	5
281	Renal denervation: one step backwards, three steps forward. <i>Nature Reviews Nephrology</i> , 2018, 14, 602-604.	4.1	5
282	New Molecules for Treating Resistant Hypertension: a Clinical Perspective. <i>Current Hypertension Reports</i> , 2019, 21, 80.	1.5	5
283	Ambulatory blood pressure monitoring and morning surge in blood pressure in adult black and white South Africans. <i>Journal of Clinical Hypertension</i> , 2020, 22, 21-28.	1.0	5
284	May Measurement Month 2018: results of blood pressure screening from 41 countries. <i>European Heart Journal Supplements</i> , 2020, 22, H1-H4.	0.0	5
285	Delayed retinal vein recovery responses indicate both non-adaptation to stress as well as increased risk for stroke: the SABPA study. <i>Cardiovascular Journal of Africa</i> , 2021, 32, 7-18.	0.2	5
286	Role of the sympathetic nervous system in cardiometabolic control: implications for targeted multiorgan neuromodulation approaches. <i>Journal of Hypertension</i> , 2021, 39, 1478-1489.	0.3	5
287	Homocysteine predicts vascular target organ damage in hypertension and may serve as guidance for first-line antihypertensive therapy. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1380-1389.	1.0	5
288	Renal, Cardiac, and Autonomic Effects of Catheter-Based Renal Denervation in Ovine Heart Failure. <i>Hypertension</i> , 2021, 78, 706-715.	1.3	5

#	ARTICLE	IF	CITATIONS
289	Microvascular changes at different stages of chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2021, 23, 309-316.	1.0	5
290	A standardized protocol for evaluation of large extracellular vesicles using the attune [®] , [®] NXT system. <i>Journal of Immunological Methods</i> , 2021, 499, 113170.	0.6	5
291	Sympathetic stimulation with norepinephrine may come at a cost. <i>Neural Regeneration Research</i> , 2019, 14, 977.	1.6	5
292	Circulating platelet-derived extracellular vesicles correlate with nighttime blood pressure and vascular organ damage and may represent an integrative biomarker of vascular health. <i>Journal of Clinical Hypertension</i> , 2022, 24, 738-749.	1.0	5
293	Renal and Systemic Hemodynamics in Black and White Hypertensive Patients. <i>American Journal of Hypertension</i> , 1997, 10, 971-978.	1.0	4
294	Renal denervation for resistant hypertension—the Symplicity HTN-1 study — Authors' reply. <i>Lancet</i> , The, 2014, 383, 1885-1886.	6.3	4
295	A cautionary note for researchers treating mice with the neurotransmitter norepinephrine. <i>Biochemistry and Biophysics Reports</i> , 2018, 15, 103-106.	0.7	4
296	May Measurement Month 2017: an analysis of the blood pressure screening campaign results in Indonesia—South-East Asia and Australasia. <i>European Heart Journal Supplements</i> , 2019, 21, D63-D65.	0.0	4
297	Self-monitoring of blood pressure to guide titration of antihypertensive medication—a new era in hypertension management?. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 94-99.	0.7	4
298	May Measurement Month 2018: an analysis of blood pressure screening results from Australia. <i>European Heart Journal Supplements</i> , 2020, 22, H17-H19.	0.0	4
299	Interventional Approaches for Loin Pain Hematuria Syndrome and Kidney-Related Pain Syndromes. <i>Current Hypertension Reports</i> , 2020, 22, 103.	1.5	4
300	The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF- α . <i>Journal of Clinical Medicine</i> , 2020, 9, 2764.	1.0	4
301	An evaluation of empagliflozin and its applicability to hypertension as a therapeutic option. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1157-1166.	0.9	4
302	Therapeutic inertia in hypertension management — status quo in primary care. <i>Journal of Hypertension</i> , 2021, 39, 1107-1108.	0.3	4
303	Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 135-141.	1.0	4
304	Global Impact of Different Blood Pressure Thresholds in 4690 Participants of the May Measurement Month Initiative. <i>Hypertension</i> , 2022, 79, 1497-1505.	1.3	4
305	Dabigatran elimination: is haemodialysis effective?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 580-581.	1.8	3
306	Residual Sympathetic Responsiveness After Catheter-Based Renal Denervation. <i>Hypertension</i> , 2016, 67, 1117-1118.	1.3	3

#	ARTICLE	IF	CITATIONS
307	Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?. <i>Current Hypertension Reports</i> , 2017, 19, 30.	1.5	3
308	The role of selective imidazoline receptor agonists in modern hypertension management: an international real-world survey (STRAIGHT). <i>Current Medical Research and Opinion</i> , 2020, 36, 1939-1945.	0.9	3
309	Differential sympathetic response to lesion-induced chronic kidney disease in rabbits. <i>Kidney International</i> , 2020, 98, 906-917.	2.6	3
310	Supine blood pressureâ€”A clinically relevant determinant of vascular target organ damage in hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2021, 23, 44-52.	1.0	3
311	May Measurement Month 2019: an analysis of blood pressure screening results from Australia. <i>European Heart Journal Supplements</i> , 2021, 23, B18-B20.	0.0	3
312	Renalase â€” a potential biomarker for risk of atrial fibrillation?. <i>Kardiologia Polska</i> , 2018, 76, 1201-1202.	0.3	3
313	Renal denervation alters ambulatory blood pressure-derived salt sensitivity index in patients with uncontrolled hypertension. <i>Journal of Hypertension</i> , 2022, 40, 570-578.	0.3	3
314	Retinal Capillary Damage Is Already Evident in Patients With Hypertension and Prediabetes and Associated With HbA1c Levels in the Nondiabetic Range. <i>Diabetes Care</i> , 2022, 45, 1472-1475.	4.3	3
315	Renal sympathetic denervation for resistant hypertension â€” Authors' reply. <i>Lancet, The</i> , 2009, 373, 2109-2110.	6.3	2
316	Hypertension on the ROX. <i>Hypertension</i> , 2017, 70, 1084-1086.	1.3	2
317	Resistant Hypertension: Which Agent?. <i>Heart Lung and Circulation</i> , 2018, 27, 911-916.	0.2	2
318	Renal denervation for treating congenital long QT syndrome: shortening the QT interval or modulating sympathetic tone?. <i>Europace</i> , 2019, 21, 1755-1756.	0.7	2
319	Machine learning powered tools for automated analysis of muscle sympathetic nerve activity recordings. <i>Physiological Reports</i> , 2021, 9, e14996.	0.7	2
320	Renal Deafferentation Prevents Progression of Hypertension and Changes to Sympathetic Reflexes in a Rabbit Model of Chronic Kidney Disease. <i>Hypertension</i> , 2021, 78, 1310-1321.	1.3	2
321	TNFSF14-Derived Molecules as a Novel Treatment for Obesity and Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10647.	1.8	2
322	No Evidence for Long Term Blood Pressure Differences Between Eversion and Conventional Carotid Endarterectomy in Two Independent Study Cohorts. <i>European Journal of Vascular and Endovascular Surgery</i> , 2022, 63, 33-42.	0.8	2
323	Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage. <i>Hypertension</i> , 2022, 79, 261-270.	1.3	2
324	Automatic data extraction from 24 hour blood pressure measurement reports of a large multicenter clinical trial. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 214, 106588.	2.6	2

#	ARTICLE	IF	CITATIONS
325	Elevated Cardiac Risk in Patients With Major Depressive Disorder. American Journal of Psychiatry, 2008, 165, 137-137.	4.0	1
326	Catheter based radiofrequency ablation of renal nerves for the treatment of resistant hypertension. Italian Journal of Medicine, 2012, 6, 105-109.	0.2	1
327	Treatment-resistant hypertensionâ€”a risk factor for ESRD. Nature Reviews Nephrology, 2014, 10, 189-190.	4.1	1
328	Microalbuminuria â€” an important marker of residual risk. Journal of Hypertension, 2016, 34, 627-628.	0.3	1
329	Renal denervation for resistant hypertension. Journal of Hypertension, 2016, 34, 1505-1506.	0.3	1
330	Renal denervation in less severe forms of (resistant) hypertensionâ€”Quo vadis?. Journal of Clinical Hypertension, 2017, 19, 369-370.	1.0	1
331	May measurement month 2017â€”a concerted global effort to raise awareness of elevated blood pressure. Journal of Human Hypertension, 2018, 32, 319-320.	1.0	1
332	Stressing the metabolic powers of fibroblast growth factor 21. AME Medical Journal, 2018, 3, 97-97.	0.4	1
333	New insights about postâ€”exercise albuminuria in hypertensive patients. Journal of Clinical Hypertension, 2019, 21, 1180-1182.	1.0	1
334	Shaping the future of renal denervation-the relevance of sham-controlled randomized trials and recent meta-analyses. Cardiovascular Diagnosis and Therapy, 2019, 9, 601-606.	0.7	1
335	Renal denervation as a synergistic tool for the treatment of polymorphic ventricular ectopic beats. Medicine (United States), 2020, 99, e21098.	0.4	1
336	Vascular compression of the rostral ventrolateral medulla: a relevant indicator of sympathetically driven blood pressure variability?. Journal of Hypertension, 2020, 38, 2380-2381.	0.3	1
337	The role of afferent renal denervation in renovascular hypertensionâ€”another brick in the wall. Pflugers Archiv European Journal of Physiology, 2020, 472, 323-324.	1.3	1
338	Sympathetic hyperactivity after coronary artery bypass graft surgery: an important player in the development of postoperative atrial fibrillation?. Europace, 2021, 23, 158-158.	0.7	1
339	Blunted natriuretic response to saline loading in sheep with hypertensive kidney disease following radiofrequency catheter-based renal denervation. Scientific Reports, 2021, 11, 14795.	1.6	1
340	Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients. Journal of Human Hypertension, 2021, , .	1.0	1
341	Renal Denervation And Pulmonary Vein Isolation In Patients With Drug Resistant Hypertension And Symptomatic Atrial Fibrillation. Journal of Atrial Fibrillation, 2014, 7, 1165.	0.5	1
342	K-means panning â€” Developing a new standard in automated MSNA signal recognition with a weakly supervised learning approach. Computers in Biology and Medicine, 2022, 140, 105087.	3.9	1

#	ARTICLE	IF	CITATIONS
343	Hypertension With Negative Metaiodobenzylguanidine Scintigraphy. <i>Hypertension</i> , 2022, 79, 474-478.	1.3	1
344	Autoencoded deep features for semi-automatic, weakly supervised physiological signal labelling. <i>Computers in Biology and Medicine</i> , 2022, 143, 105294.	3.9	1
345	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. <i>American Journal of Hypertension</i> , 1999, 12, 418-422.	1.0	0
346	Letter by Schlaich et al Regarding Article, "Relationship Between Central Sympathetic Drive and Magnetic Resonance Imaging-Determined Left Ventricular Mass in Essential Hypertension"; <i>Circulation</i> , 2007, 116, e416; author reply e417.	1.6	0
347	Rebuttal from Esler, Lambert, and Schlaich. <i>Journal of Applied Physiology</i> , 2010, 109, 2000-2001.	1.2	0
348	Response to Letter Regarding Article, "Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study"; <i>Circulation</i> , 2011, 124, .	1.6	0
349	Catheter based radiofrequency ablation of renal nerves for the treatment of resistant hypertension. <i>Italian Journal of Medicine</i> , 0, , 105-109.	0.2	0
350	Response to Letter Regarding Article, "Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension"; <i>Circulation</i> , 2014, 129, e500-1.	1.6	0
351	Rebuttal from Markus P. Schlaich, Yusuke Sata and Murray D. Esler. <i>Journal of Physiology</i> , 2014, 592, 3947-3947.	1.3	0
352	Response to More Research Is Needed to Investigate the Effect of Denervation on Blood Pressure. <i>Hypertension</i> , 2014, 63, e86.	1.3	0
353	Baroreflex Sensitivity. <i>Journal of the American College of Cardiology</i> , 2014, 64, 232-233.	1.2	0
354	Potential future denervation targets. <i>Interventional Cardiology</i> , 2014, 6, 569-579.	0.0	0
355	Response to Letter to the Editor by Drs. Yang and Yu entitled: Renal denervation in patients with chronic kidney disease. <i>International Journal of Cardiology</i> , 2017, 235, 190.	0.8	0
356	Renal Denervation: Current Opinions and Practice. , 2017, , 419-426.		0
357	Suitability for catheter-based renal denervation"lessons from "super-responders"™. <i>Journal of Hypertension</i> , 2018, 36, 1475-1476.	0.3	0
358	Reply. <i>Journal of Hypertension</i> , 2018, 36, 1606-1607.	0.3	0
359	Diuretics and skin cancer. <i>Journal of Hypertension</i> , 2019, 37, 1961-1962.	0.3	0
360	Shades of grey: a matter relevant to sympathetic activity and blood pressure control?. <i>Journal of Hypertension</i> , 2020, 38, 206-207.	0.3	0

#	ARTICLE	IF	CITATIONS
361	Does sympathetic hyperactivity adversely impact on the effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure?. <i>Europace</i> , 2020, 22, 331-331.	0.7	0
362	Does sympathetic hyperactivity adversely impact on the effect of pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation?. <i>Europace</i> , 2020, 22, 506-506.	0.7	0
363	Implementation, mechanisms of impact and key contextual factors involved in outcomes of the Modification of Diet, Exercise and Lifestyle (MODEL) randomised controlled trial in Australian adults: protocol for a mixed-method process evaluation. <i>BMJ Open</i> , 2020, 10, e036395.	0.8	0
364	White Coat Hypertensionâ€”A Case for Assessing Vascular Age?. <i>American Journal of Hypertension</i> , 2020, 33, 599-601.	1.0	0
365	Renal denervation as a management strategy for hypertension: current evidence and recommendations. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 825-835.	0.6	0
366	Towards Establishing Renal Denervation as the Third Pillar in Hypertension Treatment: The RADIANCE-HTN TRIO Trial. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 2015-2017.	0.9	0
367	Devices for Hypertension. , 2013, , 230-235.		0
368	Cognitive performance in patients with resistant hypertension following renal sympathetic denervation. <i>EuroIntervention</i> , 2013, 9, 665-667.	1.4	0
369	Renal Denervation: Potential Future Implications Beyond Resistant Hypertension. , 2015, , 155-161.		0
370	The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease. , 2015, , 181-189.		0
371	The molecular basis for the neutral effect of renal denervation in patients with chronic heart failure not responding to cardiac resynchronisation therapy â€” a perspective. <i>Postepy W Kardiologii Interwencyjnej</i> , 2019, 15, 503-504.	0.1	0
372	Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. <i>World Journal of Gastroenterology</i> , 2020, 26, 3225-3235.	1.4	0
373	Renal Denervation: Physiology, Scope, and Current Evidence. , 2020, , 349-366.		0
374	Reply. <i>Journal of Hypertension</i> , 2020, 38, 2339-2340.	0.3	0